The reasons for this could include a perceived aggressive biology of the tumor leading to physician bias in favor of TARE intervention or TARE enrollment in non-transplant centers, which are more prone to managing patients with HCC having higher AFP levels. The gene discussed is AFP; the disease is hepatocellular carcinoma.